Prostate cancer

News

Bayer triples sales forecast for prostate cancer drug Nubeqa

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastati

News

After a Scottish aye, NICE says no to Lynparza for prostate ...

AstraZeneca's PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as a treatment for prostate cancer, according to cost effectiveness agency NICE.<

News

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

Bayer's Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand its eligible patient population thanks to new phase 3 data.<

News

Helix web tool guides prostate cancer genetic testing

A web-based digital tool called Helix could help clinicians identify patients with prostate cancer who would benefit from genetic testing and counselling, according to researchers in the US

News

PROpel study backs Lynparza combo in first-line prostate can...

AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see the drug's use broadened after a p

News